Mark Bachleda
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Mark Bachleda
Galera Therapeutics, Inc. reported in an 8-K filed August 10, 2023 that Mark Bachleda was terminated as Chief Commercial Officer, effective August 9, 2023. The proxy statement of Galera Therapeutics, Inc. reports total compensation of $788,626 for Mark Bachleda in fiscal 2022, including a base salary of $475,000. Disclosed compensation is on record for 2 fiscal years.
“On August 9, 2023, Mark Bachleda, Pharm.D., the Company's Chief Commercial Officer, was informed that his position was being eliminated in connection with the Workforce Reduction.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Galera Therapeutics, Inc. (GRTXD)
Proxy statement
Start not stated–2023-08-09
Company network
Recorded roles and call appearances connecting this person to public companies.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2022 | Galera Therapeutics, Inc. (GRTXD) | Pharm.D., Chief Commercial Officer | $475,000 | $788,626 |
| 2021 | Galera Therapeutics, Inc. (GRTXD) | Pharm.D., Chief Commercial Officer | $109,920 | $1,288,415 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.